Deutsche Märkte geschlossen
Nikkei 225
38.236,07 -37,98 (-0,10%) Dow Jones 30
38.269,51 +366,22 (+0,97%) Bitcoin EUR
55.340,98 +38,24 (+0,07%) CMC Crypto 200
1.277,40 +6,66 (+0,52%) Nasdaq Compositive
15.849,73 +244,25 (+1,57%) S&P 500
5.069,77 +51,38 (+1,02%)
Lexaria Bioscience Corp. (LEXX)
NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
Ab 02:59PM EDT. Markt geöffnet.
Interaktives Chart wird geladen ...
- ACCESSWIRE
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability,
